Top Liver Cancer Abstracts to Watch at ASCO GI 2025
By Richard S. Finn, MD - Last Updated: January 22, 2025Richard Finn, MD, medical oncologist at the Geffen School of Medicine at UCLA, previews key abstracts in hepatobiliary malignancies from the 2025 ASCO Gastrointestinal Cancers Symposium. Dr. Finn reviews updates on pivotal trials, including the ACCELERATE study in resected gallbladder cancer, groundbreaking research in early-stage liver cancer like the LEAP-012 study, and new findings on systemic treatments in advanced liver cancer. Stay tuned for insights on immunotherapy combinations, novel therapeutic strategies, and data that could shape the future of liver cancer care.
Advertisement
Post Tags:ASCO GI 2025: Focus on Liver Cancer
Advertisement
Related Posts
The addition of concurrent chemoradiation to chemotherapy can improve OS and resection rates in patients with LAGBC.
LEAP-002 long-term follow-up suggests there may be benefit associated with len/pembro for patients with aHCC.
Dina Ioffe, MD, Fox Chase Cancer Center, talks about the use of immunotherapy in the neoadjuvant or adjuvant setting.
Researchers evaluated the efficacy and safety of hepatic arterial infusion chemotherapy as a first-line treatment option.
Dr. Christopher Lieu shares his top liver-directed therapies for metastatic colorectal cancer with liver involvement.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.